Author byline as per print journal: Professor Pere Gascón, MD; Ruediger Jankowsky, PhD; Karsten Roth, PhD
|Abstract: Cinfa Biotech, the biosimilars company of the Cinfa Group, held an international webcast to discuss pegfilgrastim and the prospective pegfilgrastim biosimilar approaches to treat chemotherapy-induced neutropenia. Professor Dr Pere Gascón delivered a talk on perspectives of pegfilgrastim. The webinar finalized with a talk on the B12019 clinical development programme by Dr Karsten Roth and a well-supported conclusion by Dr Ruediger Jankowsky that biosimilars are a necessity for supportive care in oncology. Webinar participants were made up of industry decision-makers, clinical research specialists and expert members of the international biosimilar community, such as analysts, practitioners and reporters.|
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.